RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00055227.xml
Nephrologie aktuell 2024; 28(02): 56-61
DOI: 10.1055/a-2192-4493
DOI: 10.1055/a-2192-4493
Schwerpunkt
Nephrologie
Epos EPO
Eine unverzichtbare Therapieoption bei renaler Anämie?
ZUSAMMENFASSUNG
Die Substitution des Hormons Erythropoetin (EPO) stellte bisher den Grundpfeiler der Therapie der renalen Anämie bei nierenkranken Patienten*innen dar. Die seit über 30 Jahren in der Praxis etablierte Anwendung macht die verwendeten rekombinanten Substanzen zu Medikamenten, für die ein reicher Erfahrungsschatz vorliegt. Aufgrund seiner umschriebenen Wirkweise, des bekannten Nebenwirkungsprofils sowie der aktuellen Studienlage, die bisher überwiegend eine Gleichwertigkeit gegenüber neuen Erythropoese stimulierenden Agenzien (ESA) zeigt, ist wohl kein Ende der EPO-Substitutionstherapie abzusehen. Die Therapie der renalen Anämie wird allerdings durch neue Erkenntnisse zum Eisenhaushalt sowie die nun zugelassenen HIF-Stabilisatoren optimiert und individualisiert werden können.
Publikationsverlauf
Artikel online veröffentlicht:
21. März 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13: 504-510 DOI: 10.1681/asn.V132504.
- 2 Astor BC, Muntner P, Levin A. et al Association of Kidney Function With Anemia: The Third National Health and Nutrition Examination Survey 1988–1994. Archives of Internal Medicine 2002; 162: 1401-1408 DOI: 10.1001/archinte.162.12.1401.
- 3 Wu H, Liu X, Jaenisch R. et al Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83: 59-67 DOI: 10.1016/0092-8674(95)90234-1.
- 4 Lacombe C, Da Silva JL, Bruneval P. et al Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. The Journal of clinical investigation 1988; 81: 620-623 DOI: 10.1172/JCI113363.
- 5 Paliege A, Rosenberger C, Bondke A. et al Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int 2010; 77: 312-318 DOI: 10.1038/ki.2009.460.
- 6 Kragesteen BK, Giladi A, David E. et al The transcriptional and regulatory identity of erythropoietin producing cells. Nature Medicine 2023; 29: 1191-1200 DOI: 10.1038/s41591-023-02314-7.
- 7 Chung EYM, Palmer SC, Saglimbene VM. et al Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database of Systematic Reviews 2023: 2023 DOI: 10.1002/14651858.CD010590.pub3
- 8 Besarab A, Bolton WK, Browne JK. et al The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590 DOI: 10.1056/nejm199808273390903.
- 9 Singh AK, Szczech L, Tang KL. et al Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098 DOI: 10.1056/NEJMoa065485.
- 10 Drüeke TB, Locatelli F, Clyne N. et al Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084 DOI: 10.1056/NEJMoa062276.
- 11 Pfeffer MA, Burdmann EA, Chen CY. et al A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032 DOI: 10.1056/NEJMoa0907845.
- 12 Raichoudhury R, Spinowitz BS. Treatment of anemia in difficult-to-manage patients with chronic kidney disease. Kidney Int Suppl (2011) 2021; 11: 26-34 DOI: 10.1016/j.kisu.2020.12.006.
- 13 Koulouridis I, Alfayez M, Trikalinos TA. et al Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013; 61: 44-56 DOI: 10.1053/j.ajkd.2012.07.014.
- 14 Bohlius J, Schmidlin K, Brillant C. et al Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. The Lancet 2009; 373: 1532-1542 DOI: 10.1016/S0140-6736(09)60502-X.
- 15 Tonia T, Mettler A, Robert N. et al Erythropoietin or darbepoetin for patients with cancer. Cochrane database of systematic reviews 2012; 12: CD003407 DOI: 10.1002/14651858.CD003407.pub5.
- 16 Bonomini M, Di Liberato L, Sirolli V. Treatment Options for Anemia in Kidney Transplant Patients: A Review. Kidney Med 2023; 05: 100681 DOI: 10.1016/j.xkme.2023.100681.
- 17 Yabu JM, Winkelmayer WC. Posttransplantation Anemia: Mechanisms and Management. Clinical J Am Soc Nephrol 2011; 06: 1794-1801 DOI: 10.2215/CJN.01190211.
- 18 Martinez F, Kamar N, Pallet N. et al High Dose Epoetin Beta in the First Weeks Following Renal Transplantation and Delayed Graft Function: Results of the Neo-PDGF Study. American Journal of Transplantation 2010; 10: 1695-1700 DOI: 10.1111/j.1600-6143.2010.03142.x.
- 19 Tsujita M, Kosugi T, Goto N. et al The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial. Nephrol Dial Transplant 2019; 34: 1409-1416 DOI: 10.1093/ndt/gfy365.
- 20 Choukroun G, Kamar N, Dussol B. et al Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol 2012; 23: 360-368 DOI: 10.1681/asn.2011060546.
- 21 Malyszko J, Basak G, Batko K. et al Haematological disorders following kidney transplantation. Nephrol Dial Transplant 2022; 37: 409-420 DOI: 10.1093/ndt/gfaa219.
- 22 Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 09 (Suppl. 03) S1-S155 DOI: 10.1111/j.1600-6143.2009.02834.x.
- 23 Cournoyer D, Toffelmire EB, Wells GA. et al Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004; 15: 2728-2734 DOI: 10.1097/01.ASN.0000140219.28618.9F.
- 24 Boven K, Stryker S, Knight J. et al The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67: 2346-2353 DOI: 10.1111/j.1523-1755.2005.00340.x.
- 25 Chapter 1: Diagnosis and evaluation of anemia in CKD Kidney Int Suppl (2011). 2012; 02: 288-291 DOI: 10.1038/kisup.2012.33.
- 26 Schwartz DI, Pierratos A, Richardson RM. et al Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol 2005; 63: 202-208 DOI: 10.5414/cnp63202.
- 27 Chan CT, Liu PP, Arab S. et al Nocturnal hemodialysis improves erythropoietin responsiveness and growth of hematopoietic stem cells. J Am Soc Nephrol 2009; 20: 665-671 DOI: 10.1681/ASN.2008050498.
- 28 Beusterien KM, Nissenson AR, Port FK. et al The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 07: 763-773 DOI: 10.1681/asn.V75763.
- 29 Parfrey PS, Foley RN, Wittreich BH. et al Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189 DOI: 10.1681/asn.2004121039.
- 30 Johansen KL, Cobitz AR, Singh AK. et al The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease. Kidney Int 2023; 103: 1180-1192 DOI: 10.1016/j.kint.2023.02.019.
- 31 Macdougall IC, White C, Anker SD. et al Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. N Engl J Med 2018; 380: 447-458 DOI: 10.1056/NEJMoa1810742.